CHICAGO — Time between therapy regimens can safely be offered to certain children with cancer to promote quality of life and explore goals of care without negatively affecting survival, according to data presented at ASCO Annual Meeting.
The results, researchers said, point toward a potentially industry-wide underappreciation for delays in treatment among pediatric patients with relapsed or refractory solid tumors.
“Most children with relapsed solid tumors will go on to experience multiple relapse events and subsequent therapy without ever having a break in receiving some kind of